Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Prog Community Health Partnersh ; 18(1): 113-119, 2024.
Article in English | MEDLINE | ID: mdl-38661832

ABSTRACT

BACKGROUND: People experiencing homelessness are at increased risk of infectious disease transmission due to congregate living conditions, barriers to healthcare, and excess burden of underlying chronic disease. OBJECTIVES: We are a multisectoral community-academic partnership working to address the intersecting crises of homelessness and health disparities in Tippecanoe County, Indiana. We offer key recommendations for infectious disease preparedness and risk mitigation for homeless populations based on our ongoing community-based participatory research and lessons learned through COVID-19 response and Monkeypox preparations. LESSONS LEARNED: Infectious disease preparedness and response in homeless populations requires strong local partnerships; ongoing training and support for staff and volunteers of homeless shelters and service agencies; tailored outreach, education, and communication with people experiencing homelessness; and standardized processes for creating, disseminating, enforcing, and evaluating public health policies in homeless shelters. Consistency and open communication are key to a successful community-academic partnership. CONCLUSIONS: Community-academic partnerships are critical to effective infectious disease preparedness in homeless populations. The lessons learned from community-based participatory research with homeless communities and multisectoral partners on the frontline can improve future outbreak and pandemic response for people experiencing homelessness and other vulnerable communities in the United States.


Subject(s)
COVID-19 , Community-Based Participatory Research , Community-Institutional Relations , Ill-Housed Persons , Humans , Community-Based Participatory Research/organization & administration , COVID-19/prevention & control , COVID-19/epidemiology , Indiana/epidemiology , SARS-CoV-2 , Communicable Disease Control/organization & administration , Communicable Disease Control/methods
3.
Eur J Gastroenterol Hepatol ; 18(6): 607-14, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16702849

ABSTRACT

OBJECTIVES: Radiolabelled white cell scans provide non-invasive quantification of inflammatory activity. Clinical activity scores measure severity of disease but are partly subjective. White cell scans may provide a suitable method of monitoring the treatment response of active inflammatory bowel disease. METHODS: Ten subjects with active ulcerative colitis and 13 subjects with active Crohn's disease were recruited. White cell scans were carried out before and 2 weeks after treatment. Prior to each scan, activity scores for ulcerative colitis or Crohn's disease were calculated and serum and faecal tumour necrosis factor-alpha and calprotectin measured. White cell scan activity at 1 h was calculated by using a validated visual grading system. RESULTS: Following anti-inflammatory treatment, 70% of white cell scans improved, 17% remained unchanged and 13% deteriorated. In the ulcerative colitis subgroup subjects there was modest agreement for change in scan score and activity scores. In the Crohn's disease subjects there was better agreement between change of white cell scan score and clinical scores. Planar white cell scans correlated with the van Hees activity index (r=0.68, P=0.002) and faecal calprotectin (r=0.58, P=0.0003). Changes in planar white cell scans correlated with changes in serum calprotectin (r=0.45, P=0.05). CONCLUSION: Non-invasive white cell scanning is a feasible and objective method to monitor the anti-inflammatory efficacy of treatments for active inflammatory bowel disease.


Subject(s)
Colitis, Ulcerative/diagnosis , Crohn Disease/diagnosis , Feces/chemistry , Leukocyte L1 Antigen Complex/blood , Phagocytes/physiology , Tumor Necrosis Factor-alpha/blood , Adult , Anti-Inflammatory Agents/therapeutic use , Biomarkers/analysis , Colitis, Ulcerative/blood , Colitis, Ulcerative/drug therapy , Crohn Disease/blood , Crohn Disease/drug therapy , Female , Humans , Male , Middle Aged , Prednisolone/therapeutic use , Radiopharmaceuticals , Technetium Tc 99m Exametazime
SELECTION OF CITATIONS
SEARCH DETAIL
...